Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 4/20 | 0.45 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.39 |
| ▸ | RBP4 | P02753 | 1/20 | 0.39 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13691391 | 0.89 | GPR119 (0.53) | PARP10PARP15GPR119JAK2SCN9A | |
| SCHEMBL4050230 | 0.87 | PDE4B (0.45) | PARP10PARP15CHEK2 | |
| SCHEMBL4540555 | 0.86 | CHRM4 (0.43) | FFAR4GPR119RBP4 | |
| SCHEMBL4051411 | 0.80 | RBP4 (0.37) | FFAR4RBP4 | |
| SCHEMBL4455486 | 0.80 | PARP10 (0.49) | PARP10PARP15FFAR4GPR119RBP4 | |
| SCHEMBL4373911 | 0.79 | CLK4 (0.42) | GPR119RBP4 | |
| SCHEMBL4058702 | 0.79 | SLC6A9 (0.49) | GPR119 | |
| SCHEMBL4051573 | 0.78 | CCR5 (0.41) | RBP4 | |
| SCHEMBL4051853 | 0.77 | GPR119 (0.44) | GPR119RBP4 | |
| SCHEMBL3978055 | 0.76 | GPR119 (0.60) | PARP10PARP15FFAR4GPR119CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009106565-A1 | AGONISTS OF GPR119 | BIOVITRUM AB (PUBL) (SE) | 2009-09-03 | — | — | WO | disclosed |